12/1/2023

Octreotide Injection

Products Affected - Description

- Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
- Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-01
- Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-01
- Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10

Reason for the Shortage

- Avet has octreotide available.
- Fresenius Kabi had octreotide on shortage due to manufacturing delays.
- Hikma did not provide a reason for the shortage.
- Sagent discontinued octreotide in March 2023.
- Sun Pharma discontinued Bynfezia Pen in 2021.
- Teva discontinued octreotide in April 2022.
- Viatris did not provide a reason for the shortage.
- Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.

Available Products

- Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
- Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
- Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
- Octreotide Acetate injection, Avet Pharmaceuticals, 100 mcg/mL, 1 mL vial, 10 count, NDC 23155-0688-41
- Octreotide Acetate injection, Avet Pharmaceuticals, 1000 mcg/mL, 5 mL vial, 1 count, NDC 23155-0686-31
- Octreotide Acetate injection, Avet Pharmaceuticals, 200 mcg/mL, 5 mL vial, 1 count, NDC 23155-0685-31
- Octreotide Acetate injection, Avet Pharmaceuticals, 50 mcg/mL, 1 mL vial, 10 count, NDC 23155-0687-41
- Octreotide Acetate injection, Avet Pharmaceuticals, 500 mcg/mL, 1 mL vial, 10 count, NDC 23155-0689-41
- Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
- Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
- Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
- Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
- Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
- Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
- Octreotide Acetate injection, Mylan Institutional (Viatris), 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
- Octreotide Acetate injection, Mylan Institutional (Viatris), 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
- Octreotide Acetate injection, Mylan Institutional (Viatris), 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01

Estimated Resupply Dates

- Hikma has octreotide 200 mcg/mL 5 mL vials and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of early-December 2023 for the 200 mcg/mL 5 mL vials and late-December 2023 for the 1,000 mcg/mL 5 mL vials.
- Fresenius Kabi has octreotide 200 mcg/mL 5 mL vials on back order and the company cannot estimate a release date.

Updated

Updated December 1, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.